Create a narrative

Silence Therapeutics Community

NasdaqGM:SLN Community

1 Narratives written by author
1 Comments on narratives written by author
11 Fair Values set on narratives written by author

Create a narrative

Silence Therapeutics

AN

AnalystConsensusTarget

AnalystConsensusTarget

Consensus Narrative from 7 Analysts

ALPACAR-360 Success And AstraZeneca Collaboration Will Advance siRNA Pipeline

Key Takeaways The company's strategic partnerships and collaborations could reduce financial risk and enhance revenue growth through shared commercialization and milestone payments. Successful study results and orphan drug designation might lead to dominance in niche markets, improving future earnings and net margins.

US$23.84

FV

74.7% undervalued

61.65%

Revenue growth p.a.

0

1

9

5 days ago